Gray accepts VP position with Trex Medical
Trex Medical has hired Dr. Joel Gray as vice president of business and clinical development. Gray was hired for his imaging expertise as the company prepares for premarket approval of its full-field digital mammography system this year, said
Trex Medical has hired Dr. Joel Gray as vice president of business and clinical development. Gray was hired for his imaging expertise as the company prepares for premarket approval of its full-field digital mammography system this year, said William Webb, Trex president and CEO.
Gray will oversee the final stages of development of Lorads digital mammography unit. Lorad is Trexs mammography division.
Gray was a medical physicist in the Mayo Clinics radiology department for 20 years. For the past four years, he has been an independent consultant in medical technology management and assessment, medical physics, and imaging sciences for healthcare organizations and the medical imaging industry. He also worked with several overseas organizations to promote quality medical imaging.
Trex Medical, owned by Thermo Electron, is up for sale. Thermo Electron announced earlier this year it would seek a buyer.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
